In nonsquamous NSCLC, the CheckMate 057 trial demonstrated that nivolumab improved the 1-year and 18-month OS regardless of PD-L1 expression level but had improved outcomes with increased levels of tumor-membrane expression of the PD-1 ligand. Here, CD274 is linked to neoplasm.